White Faslodex For Breast Cancer Treatment Hormones Powder CAS 129453-61-8

Basic Information
Place of Origin: China
Brand Name: Senwayer Brand
Certification: ISO, 9001, USP
Model Number: 129453-61-8
Minimum Order Quantity: 10grams
Price: Discount is possible if your order is big enough
Packaging Details: 10g, 20g, 50g , 100g, 500g. 1kg, 10kg
Delivery Time: within 2 working days
Payment Terms: T/T in advance, Money Gram, Western Union, Bank Transfer.
Supply Ability: 1000kg/month
Detail Information
CAS: 129453-61-8 Alias: Fulvestrant , Faslodex
Apparence: Almost White Crystalline Powder Purity: 99%
High Light:

antineoplastic drugs


breast cancer drugs

Product Description

Mediacal Faslodex For Breast Cancer Treatment Hormones 129453-61-8 White Powder


Quick detail

Product Name Fulvestrant , Faslodex
Chemical Name Faslodex
CAS Number 129453-61-8
Molecular Formula C32H47F5O3S
Molecular Weight 606.77
Melting Point 104-106ºC
Assay 99.5%
Appearance White powder
Product Categories Intermediates & Fine Chemicals;Pharmaceuticals;Nuclear Receptors;Chiral Reagents;Steroids;Sulfur & SeleniumCompounds;FASLODEX;Anti-cancer&immunity;Inhibitors


Fulvestrant Description:

Fulvestrant, sold under the trade name Faslodex among others, is used to treat hormone receptor positive breast cancer (breast cancer that depends on hormones such as estrogen to grow) in women who have experienced menopause (change of life; end of monthly menstrual periods) and whose breast cancer has worsened after they were treated with antiestrogen medications such as tamoxifen (Nolvadex). It works to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with palbociclib in women with disease progression after endocrine therapy. It is given by injection into a muscle.


Fulvestrant is approved to treat:

Breast cancer in postmenopausal women. It is used in patients with estrogen receptor positive breast cancer that has metastasized (spread to other parts of the body) after treatment with other antiestrogens.


Usual Adult Dose for Breast Cancer

Initial dose: 500 mg IM on days 1, 15, and 29, then once a month thereafter.

Renal Dose Adjustments
CrCl 30 mL/min or more: No adjustment recommended

CrCl 29 mL/min or less: Data not available

Liver Dose Adjustments
Mild liver function (Child-Pugh class A): No specific dose adjustment guidelines have been suggested; however, caution is recommended.

Moderate liver dysfunction (Child-Pugh class B): 250 mg IM on days 1, 15, and 29, then once a month thereafter.

Severe liver dysfunction (Child-Pugh class C): Data not available



Women of childbearing age should be advised not to become pregnant while receiving fulvestrant.

Because fulvestrant is administered intramuscularly it should be used with caution in patients with bleeding diatheses, thrombocytopenia, or patients on anticoagulants.

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).


Fulvestrante COA:

Test Item Specification Results
Appearance A white to off-white crystalline powder A white crystalline powder
Identification IR Conform
Any Individual impurity Not more than 0.10% 0.18%
Total impurities Not more than 1.0% 0.44%

Ratio of isomers
50.0%-60.0% 51.70%
40.0%-50.0% 47.86%
Purity 99.0% 99.56%

Contact Details
Abby Xiang

Phone Number : +8617764031156

WhatsApp : +8617764031156